# Mays Cancer Center at UT Health SA

> **NIH NIH P30** · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · 2020 · $32,570

## Abstract

Project Summary-Cancer Development and Progression (CDP) Program
The Cancer Development and Progression (CDP) Program is one of three highly interactive research programs
of the Mays Cancer Center (MCC) at the University of Texas Health San Antonio (UT Health SA). Patrick Sung,
D.Phil. and Ratna K. Vadlamudi, Ph.D. are Co-Leaders of the Program. The CDP Program focuses on
laboratory-based studies of fundamental problems in cancer etiology and progression and also clinical translation
of our research findings. The Program has two thematic areas: 1) Genomic Repair and Epigenetics and 2) Tumor
Microenvironment. Through these foci, the CDP Program continues to make important contributions toward the
MCC’s goal of cancer prevention and treatment, particularly for those disproportionate in our largely Hispanic
population in South Texas. The Program’s Specific Aims are to: 1) Pursue basic and translational research to
discover cancer-specific genome alterations, DNA repair mechanisms, and epigenetic programming that can be
effectively translated to the clinic; and 2) Discover mechanisms and identify new therapeutic targets for
modulating tumor metastases, paracrine signaling, immune signaling, and metabolism. The CDP Program has
29 members. They represent eight different academic departments in the Long School of Medicine at UT Health
SA, and one member is from the University of Texas at Austin. CDP Program members hold $11.7M in peer-
reviewed cancer-related funding (47 grants; direct costs). NCI provides $1.7M in funding (through 12 grants).
Over the last reporting period, CDP Program members have published 260 peer-reviewed papers. Of these,
26% were products of intra-programmatic collaborations, 21% of inter-programmatic collaborations, and 77%
involved multi-institutional collaborations, including 84 (42%) publications with other NCI-designated Cancer
Centers. CDP members continue to use Cancer Center-supported cores extensively in their research, most
notably, Next Generation Sequencing, Biostatistics and Bioinformatics, Mass Spectrometry, Flow Cytometry,
and Drug Discovery and Structural Biology facilities. CDP scientific accomplishments over the past five years
have resulted in several paradigm-shifting findings, high-impact publications (e.g. Nature, Cell, Molecular Cell,
Nature Communications), development of novel models for defining cancer development and progression
mechanisms, an antibody-based therapeutic for metastatic breast cancer, new estrogen receptor-beta agonists
for enhancing tumor suppression, and small molecule inhibitors for treating endocrine therapy resistance. CDP
members –including successful new recruits whose work expands our program’s focus – work closely with the
Experimental and Developmental Therapeutics (EDT) Program to move research into the clinic. Multiple grants
are already underway to pursue these hypotheses, with others in review and planned for upcoming submissions.
In the last reporting period, two clinical t...

## Key facts

- **NIH application ID:** 10025093
- **Project number:** 2P30CA054174-25
- **Recipient organization:** UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
- **Principal Investigator:** Ratna K Vadlamudi
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $32,570
- **Award type:** 2
- **Project period:** 1997-08-01 → 2025-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10025093

## Citation

> US National Institutes of Health, RePORTER application 10025093, Mays Cancer Center at UT Health SA (2P30CA054174-25). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10025093. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*